UK-based pharmaceutical company AstraZeneca Plc (AZN) is reportedly interested in a potential merger with rival drugmaker Gilead Sciences Inc. (GILD) in what would …
Shares in Gilead Sciences (GILD) traded down 3.4% on Monday after the company announced topline results from its Phase 3 SIMPLE trial in …
Gilead Sciences (GILD) and Arcus Biosciences (RCUS), an oncology-focused biopharma, have announced a 10-year partnership to co-develop and co-commercialize current and future therapeutic …
Gilead Sciences Inc.’s (GILD) remdesivir, its coronavirus drug candidate, is most “beneficial” for Covid-19 patients who require supplemental oxygen but don’t need mechanical …
Gilead Sciences (GILD) and Galapagos NV (GLPG) have announced positive topline results from a Phase 2b/3 trial evaluating the efficacy and safety of …
Guido Rasi, the Executive Director of the European Medicines Agency (EMA), has suggested that Gilead’s (GILD) Covid-19 treatment remdesivir could be conditionally approved …
Gilead Sciences Inc.’s (GILD) signed non-exclusive licensing agreements with five generic pharmaceutical manufacturers that will allow them to produce and sell its experimental …
The US Department of Health has now announced the allocation plan for Gilead’s (GILD) Covid-19 treatment remdesivir, revealing that states rather than federal …
Japan intends to approve Gilead’s (GILD) Covid-19 treatment remdesivir today, according to a live interview with Japan’s Prime Minister Shinzo Abe on May …
Gilead Sciences Inc.’s (GILD) said it is in talks with some of the world’s leading chemical and pharmaceutical manufacturing companies to produce its …
